Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Francesca Bruce
Plans to make Canada’s biologics market more competitive for biosimilars are advancing as payers are planning consultations on how price negotiations for biosimilars and biologics will proceed.
NICE, the HTA for England and Wales, is poised to say no to Pfizer’s Ibrance (palbociclib), because the cost of the drug is too big in relation to its benefits. The company will likely have to come back with a patient access scheme to secure reimbursement.
Sanofi/Regeneron’s Kevzara (sarilumab) has won its first worldwide approval for treating moderately to severely active rheumatoid arthritis from Health Canada. But as more regulators follow, the companies will face a battle to differentiate the drug from chief rival, Roche/Chugai’s Actemra (tocilizumab).
Product Listing Agreements are on the rise in Canada’s private medicines market, which seems set to undergo some big changes. Drug companies may have to consider adapting their economic arguments and being more transparent.
AFIDRO, the association representing Colombia’s research-based pharmaceutical industry, is taking the government to court over new pricing regulations that follow the controversial declaration of public interest for Novartis’ Glivec (imatinib).
Novartis is taking Colombian authorities to court over moves to cut the price of its anticancer Glivec (imatinib) and warns that the intellectual property rights of other products are under threat. Companies selling hepatitis C drugs should pay attention as their products could be next to face similar measures.